CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders

Principal Investigator: Sudie E. Back, PhD
Aim: Determine the efficacy of the medication doxazosin in reducing the severity of posttraumatic stress disorder and alcohol use in veterans with both PTSD and alcohol use disorder; establish guidelines for measuring progress during clinical trials involving veterans with those disorders.
Post-911 deployments have left an increasing number of U.S. military personnel and veterans at risk of developing posttraumatic stress disorder (PTSD) and substance use disorders. The most common substance use problem among veterans is alcohol use disorder (AUD).

Co-occurring PTSD and AUD complicates treatment of both conditions, but medical professionals have little scientific evidence to guide patient care.

Principal Investigator Sudie E. Back, PhD, of the Ralph H. Johnson VA in Charleston, South Carolina and the Medical University of South Carolina, and her research team are addressing that knowledge gap with this study for the Consortium to Alleviate PTSD. They will test the efficacy of doxazosin, as compared to placebo, in reducing PTSD and alcohol use severity.

Although doxazosin normally is prescribed to treat high blood pressure and enlarged prostate, the drug has shown promise in pilot studies in significantly reducing symptoms of PTSD and AUD.

Study participants will be selected randomly to receive either doxazosin or a placebo over a 12-week period, with periodic measurements of PTSD symptoms and alcohol use. All patients will receive cognitive behavioral therapy for AUD during the trial. Those assigned to placebo will have access to other treatments following the study.

Assessments will include functional magnetic resonance imaging (fMRI) before and after the study to examine physical characteristics of comorbid PTSD/AUD in the brain, as well as changes over time that indicate positive response to treatment.

This study features a multidisciplinary team of investigators with nationally recognized expertise in combat-related PTSD, substance use disorders, and neuroimaging who have successfully collaborated in the past. The investigators represent a collaboration of faculty at the Medical University of South Carolina and the Ralph H. Johnson Veterans Affairs Medical Center in Charleston, SC.

Expected benefits

The findings from this study may open a new avenue for treatment of the common and complex comorbidity of PTSD and alcohol use disorder. It has the potential to significantly improve the standard of patient care, advance the science in this area, decrease public health expenditures, and improve the military readiness and overall health of U.S. military personnel, veterans, and their families.

Version: 05/25/2017

PI: SudieBack, PhD
Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, and the Medical University of South Carolina

Study Sites:
Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC
Savannah VA Outpatient Clinic, Savannah, GA

On-Site Principal Investigator:
Sudie E. Back, PhD

Funding Source:
U.S. Departments of Defense and Veterans Affairs, Consortium to Alleviate PTSD award

Status of Study:
Currently enrolling study participants

Participants:
Veterans with co-occurring PTSD and alcohol use disorder

For more information on study participation, contact:

Aisling Henschel
(843) 577-5011 ext. 1-5335 (VA) or
(843) 876-0736 (MUSC)

henschel@musc.edu



Media Contact:
(210) 562-6700
media@strongstar.org

Copyright © 2008-2017
All rights reserved. (ssCAPWeb)
STRONG STAR Data and Statistics Core.
Contact bdcscore@uthscsa.edu
UT Health
Home About Us News STRONG STAR Projects Contact Us